A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Infusion of Danavorexton in Participants With Moderate to Severe Obstructive Sleep Apnea Undergoing General Anesthesia for Abdominal Surgery
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Danavorexton (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Takeda
Most Recent Events
- 30 Oct 2024 Status changed from recruiting to discontinued (Business decision unrelated to patient safety).
- 30 Apr 2024 Planned End Date changed from 4 Jul 2024 to 2 Mar 2025.
- 30 Apr 2024 Planned primary completion date changed from 31 May 2024 to 31 Jan 2025.